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Abstract
Lipids play a role in many biological functions and the newly emerging field of lipidomics aims to characterize the varying
classes of lipid molecules present in biological specimens. Animal models have shown associations between maternal die-
tary supplementation with fatty acids during pregnancy and epigenetic changes in their offspring, demonstrating a mecha-
nism through which prenatal environment can affect outcomes in children; however, data on maternal lipid metabolite
levels during pregnancy and newborn DNA methylation in humans are sparse. In this study, we assessed the relationship
of maternal lipid metabolites measured in the blood from pregnant women with newborn DNA methylation profiles in the
Center for the Health Assessment of Mothers and Children of Salinas cohort. Targeted metabolomics was performed by se-
lected reaction monitoring liquid chromatography and triple quadrupole mass spectrometry to measure 92 metabolites in
plasma samples of pregnant women at 26 weeks gestation. DNA methylation was assessed using the Infinium
HumanMethylation 450K BeadChip adjusting for cord blood cell composition. We uncovered numerous false discovery rate
significant associations between maternal metabolite levels, particularly phospholipid and lysolipid metabolites, and new-
born methylation. The majority of the observed relationships were negative, suggesting that higher lipid metabolites during
pregnancy are associated with lower methylation levels at genes related to fetal development. These results further eluci-
date the complex relationship between early life exposures, maternal lipid metabolites, and infant epigenetic status.
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Introduction
Metabolomics has emerged as a useful tool to examine the pro-
files of small molecule metabolites in biospecimens [1]. Factors
that have been associated with metabolite levels include age [2],
diseases such as obesity [3], genetic variants throughout the hu-
man genome [4], and epigenetics [5, 6]. Both untargeted and
targeted methodologies are commonly used in metabolomic re-
search, with the former measuring thousands of metabolites in
a biological sample and the latter focusing on a subset of metab-
olites, often involved in specific biological pathways [2]. For in-
stance, lipidomics evaluates the function and distribution of
lipids, which have a greater diversity of molecular species
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compared to the other classes of biological molecules in the
body, such as carbohydrates and amino acids [7].
Epigenetic mechanisms regulate gene expression without
changes in DNA sequence and include DNA methylation, his-
tone modifications, and non-coding RNAs [8]. DNA methylation
is the most commonly examined epigenetic mechanism and
refers to the addition of a methyl group to the C5 position of the
cytosine ring in a CpG dinucleotide by DNA methyltransferases
[9]. DNA methylation patterns are retained following somatic
cell division [10]. In the Center for the Health Assessment of
Mothers and Children of Salinas (CHAMACOS) cohort and as part
of the Pregnancy and Childhood Epigenetics consortium, we
have explored the relationship of infant DNA methylation with
early life environmental exposure of mothers to chemicals dur-
ing pregnancy, including endocrine disrupting chemicals [11–13]
and smoking [14]. Since the epigenome undergoes remodeling
and rapid cell division in the prenatal period [8], this life stage is
considered particularly sensitive to environmental insults and
can have implications for disease trajectories [15].
There remains a paucity of information on the relationship
between metabolite profiles, in general and specific to the lipid
species, and DNA methylation, particularly the link between
maternal lipid metabolites during pregnancy and offspring epi-
genetics, which could be a mechanism through which the in
utero environment exerts an effect on epigenetic mechanisms
that could impact offspring health. Most of the existing research
on this topic has been conducted in animal models and has fo-
cused on the relationship between maternal nutrition, includ-
ing dietary supplementation with fatty acids, and offspring
methylation status [16, 17]. Only one study to date has exam-
ined the association between in utero metabolic traits, including
lipid metabolites, and DNA methylation profiles in newborns
[5]. The authors found significant relationships between mater-
nal fatty acid levels and newborn methylation globally and at
target genes related to early growth.
Previous research in the CHAMACOS cohort examined the
association between maternal prenatal phthalate urine metabo-
lite levels and targeted metabolomic compounds present in
plasma and urine, collected at 26 weeks gestation [18]. In
addition, we assessed the relationship between pre-pregnancy
body mass index (BMI) and maternal metabolomics profiles. We
observed numerous associations of metabolomic markers in-
volved in lipid and nucleic acid metabolism and the inflamma-
tory response with both urinary phthalate metabolites and
maternal BMI. This study aims to determine the association be-
tween maternal metabolomic profiles in pregnancy and child
DNA methylation at birth, emphasizing metabolites enriched
for lipid pathways that were confirmed as relevant in previous
work in CHAMACOS [18]. This study will contribute to the grow-
ing body of evidence of the influence of the early life environ-
ment on epigenetic mechanisms.
Results
Study Population
Characteristics of CHAMACOS mothers and children
included in the study are presented in Table 1. Additional
data on CHAMACOS demographic parameters have been
previously described in [19]. Most mothers were overweight
or obese (BMI 25 kg/m2) prior to pregnancy. Roughly
equal portions of children were boys and girls, 5% were of
low birth weight (<2500 g) and 7% born were premature (<37
weeks).
Maternal Prenatal Metabolomic Profiles
In this study, we focused on maternal metabolites previously
identified to be relevant to lipid biosynthesis, arachidonate en-
richment and release, and inflammatory signaling [18]. The 92
plasma metabolites in the study included fatty acids, lysolipids,
phospholipids, sphingolipids, monoacylglycerols, diacylglycer-
ols, and triacylglycerols (Table 2, Figs 1 and 2). Example distribu-
tions of specific fatty acid, lysolipid, and phospholipid
metabolites are shown in Fig. 1. Median lipid metabolite counts
ranged from 0.01 (C16:0e/C18:1 PSe) to 44 132.92 (C16:0/C18:1 PC)
(Table 2). In Fig. 2, we plotted the median values for the metabo-
lites within each of the four quartiles based on the ranges in the
metabolite distributions. The phosphatidylcholine (PC) phos-
pholipids had the highest median values and a broad range
across subjects. All metabolites were log(1þx) transformed in
analyses to reduce the influence of outliers.
Maternal Metabolomics and Newborn DNAMethylation
Analyses
Numerous maternal prenatal metabolites were significantly as-
sociated, after correcting for multiple hypotheses testing, with
DNA methylation of CHAMACOS newborns (Table 3). The
metabolites that were related to newborn DNA methylation af-
ter adjusting for relevant covariates, indicated by an asterisk
above the bar plots in Fig. 2, were distributed across the four
quartiles based on metabolite ranges, with four of the nine sig-
nificant metabolites found in the lowest quartile of ranges
(Fig. 2A). After adjusting for child sex, batch, and white blood
cell type estimates, four phospholipids (C16:0/C20:4 PS, C16:0e/
C18:1 PSe, C18:0/C20:4 alkyl PA, C18:0e/C18:1 PEe), four lysolipids
(C16:0 alkyl LPA, C18:1 alkyl LPA, C18:1 LPI, C20:4 LPS), and the
fatty acid C18:0 FFA were among the significant metabolites re-
lated to newborn methylation. The number of CpG sites signifi-
cantly associated with a specific metabolite ranged from 1 to 6.
The phospholipid C18:0/C20:4 alkyl PA, shown in Fig. 3, was one
Table 1: characteristics of CHAMACOS children and mothers (N ¼ 81
pairs) with newborn 450K data and assessment of maternal metabo-
lomic profiles at 26 weeks gestation
Characteristics
N (%)
Maternal age at delivery
18–24 32 (39.5)
25–29 36 (44.4)
30–34 11 (13.6)
35–45 2 (2.5)
Newborn sex
Boy 39 (48.1)
Girl 42 (51.9)
Mean (SD)
Maternal pre-pregnancy BMI (kg/m2) 25.5 (4.3)
Newborn gestational age (weeks) 38.8 (1.7)
Newborn birth weight (grams) 3413.1 (558.0)
Newborn white blood cell count (%)
Granulocytes 46.4 (10.3)
CD4þ T 15.5 (6.7)
CD8þ T 13.2 (3.8)
B cells 9.5 (3.2)
nRBC 10.4 (6.5)
Monocytes 8.1 (1.9)
NK cells 0.4 (1.2)
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of two phospholipid metabolites associated with methylation at
six different CpG sites, shown by the data points above the red
genome-wide significance threshold. Prior to adjustment of P-
values for multiple hypotheses testing, this metabolite was as-
sociated with 10 338 CpG sites throughout the genome. Four of
the false discovery rate (FDR) significant CpG sites associated
with C18:0/C20:4 alkyl PA were also related to C18:1 LPI.
Several CpG sites had significant relationships with one
phospholipid (C18:0/C20:4 alkyl PA) and/or two lysolipid (C16:0
alkyl LPA, C18:1 LPI) metabolites (lysolipids are phospholipid
breakdown products). For instance, cg12106728 was negatively
associated with C18:0/C20:4 alkyl PA (b ¼ 1.014, FDR P ¼ 0.005)
and C18:1 LPI (b ¼ 1.667, FDR P ¼ 0.003). A CpG site that maps
to CTDSP2 and MIR26A2, cg17169243, was inversely related to
C18:0/C20:4 alkyl PA (b ¼ 0.454, FDR P ¼ 0.019), C18:1 LPI (b ¼
0.807, FDR P ¼ 0.002), and C16:0 alkyl LPA (b ¼ 0.366, FDR P ¼
0.021). cg19220754, located in the body of TNPO1, was hypome-
thylated with increased C18:0/C20:4 alkyl PA (b ¼ 1.843, FDR P
¼ 0.019) and C18:1 LPI (b ¼ 2.962, FDR P ¼ 0.019). cg24175823
was negatively associated with C18:0/C20:4 alkyl PA (b ¼ 1.341,
FDR P ¼ 0.002), C18:1 LPI (b ¼ 2.039, FDR P ¼ 0.018), and C16:0
alkyl LPA (b ¼ 1.024, FDR P ¼ 0.018). Out of the 28 total signifi-
cant relationships between metabolites and CpG sites, 22 had
negative regression coefficients, suggesting that increased lipi-
domic levels in maternal blood are generally associated with
lower DNA methylation in their newborn children.
Although most of the significant associations were negative,
some of the positive relationships observed between maternal
metabolite levels and infant DNA methylation had the largest
effect sizes. A CpG site that maps to SEPT2 and HDLBP,
cg16787284, was positively related to C16:0e/C18:1 PSe (b ¼
25.723, FDR P ¼ 0.026) and C18:0e/C18:1 PEe (b ¼ 1.154, FDR P ¼
0.021). cg22539279, located in NEK11 and ASTE1, was also hyper-
methylated with increased C16:0e/C18:1 PSe (b ¼ 23.200, FDR P ¼
0.021).
In addition, seven of the FDR-significant relationships
remained after using the more stringent Bonferroni adjustment.
These included the associations of cg10874881 and cg16597728
with the phospholipid C16:0/C20:4 PS, cg12106728 and
cg24175823 with the phospholipid C18:0/C20:4 alkyl PA,
cg21883754 with the phospholipid ether C16:0e/C18:1 PSe, and
cg12106728 and cg17169243 with the lysolipid C18:1 LPI.
Pathway Analysis of Gene Hits
The maternal metabolites significantly associated with new-
born methylation included complex lipids and products of lipid
degradation, side products generated from choline and fatty
acid release for the developing fetus (Fig. 4A and B). These lipids
provide a methyl source for DNA methylation and drive growth,
providing lipid building blocks and energy (Fig. 4B). To deter-
mine the biological relevance of the metabolomic and methyla-
tion findings, we ran pathway analysis of the genes for which
the significant CpG hits were mapped (Table 4). The most com-
mon molecular functions relevant to the genes included binding
and catalytic activity. In addition, the genes were involved in a
range of biological processes at the cellular and metabolic levels
and participated in biological regulation, response to stimulus,
and localization. The genes BDNF, PC, and SEPT2 have been re-
lated to a variety of pathways, including Huntington disease,
pyruvate metabolism, and Parkinson disease, respectively.
Discussion
In this study, we characterized the lipidomic profiles of preg-
nant women from the CHAMACOS cohort, building upon previ-
ous research that identified associations of metabolomic data
with phthalates, endocrine disrupting chemicals, and maternal
pre-pregnancy BMI [18]. We focused on maternal metabolite
levels assessed around 26 weeks gestation, rather than at child
delivery, due to the availability of existing metabolomic data
and more importantly, to better capture exposures relevant dur-
ing fetal development that could relate to newborn epigenetic
Figure 1: representative histograms of three lipid metabolite classes: (A) a fatty
acid, C18:0 FFA; (B) a lysolipid, C18:1 alkyl LPA; and (C) a phospholipid, C18:0e/
C18:1 PEe
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Figure 2: median levels of metabolites with ranges in the (A) first (lowest), (B) second, (C) third, and (D) fourth (highest) quartiles.
*Represents metabolites that were significantly associated with DNA methylation in newborns
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Table 2: distribution of lipid metabolites in plasma of CHAMACOS mothers (N ¼ 81)
Metabolite Pathway Median IQR
C16:0/C18:1 DAG Diacylglycerol 21.56 [14.44, 30.06]
C16:0/C20:4 DAG Diacylglycerol 0.91 [0.57, 1.35]
C18:0/C18:1 DAG Diacylglycerol 6.22 [3.83, 9.53]
C18:0/C20:4 DAG Diacylglycerol 0.07 [0.04, 0.12]
C12:0 AC Fatty acid 1.12 [0.94, 1.41]
C16:0 AC Fatty acid 25.18 [14.61, 40.10]
C16:0 FFA Fatty acid 1660.35 [1282.00, 2199.70]
C18:0 AC Fatty acid 8.19 [4.08, 11.94]
C18:0 FFA Fatty acid 817.78 [664.32, 1159.16]
C18:1 FFA Fatty acid 1109.79 [732.70, 1765.65]
C20:4 FFA Fatty acid 2.96 [2.04, 3.78]
DHA Fatty acid 232.88 [39.63, 752.88]
Phytanic acid Fatty acid 4337.56 [201.02, 10 241.48]
C16:0 alkyl LPA Lysolipid 0.46 [0.20, 0.85]
C16:0 LPA Lysolipid 50.51 [40.01, 59.68]
C16:0 LPE Lysolipid 0.28 [0.15, 0.61]
C16:0 LPS Lysolipid 3.61 [2.37, 4.75]
C16:0e LPCe Lysolipid 59.15 [34.00, 85.07]
C16:0e LPCe (lysoPAF) Lysolipid 122.48 [83.12, 171.97]
C16:0e LPEe Lysolipid 3.51 [2.56, 4.35]
C18:0 LPA Lysolipid 9.77 [7.42, 13.39]
C18:0 LPE Lysolipid 1.47 [0.91, 2.80]
C18:0 LPS Lysolipid 0.11 [0.07, 0.17]
C18:0e LPEe Lysolipid 15.59 [2.80, 24.27]
C18:0e LPGe Lysolipid 0.25 [0.02, 1.12]
C18:1 alkyl LPA Lysolipid 0.54 [0.37, 0.73]
C18:1 alkyl LPI Lysolipid 1.3 [0.62, 2.88]
C18:1 LPE Lysolipid 0.43 [0.21, 1.08]
C18:1 LPI Lysolipid 0.12 [0.08, 0.17]
C18:1 LPS Lysolipid 0.41 [0.19, 0.57]
C18:1e LPCe (lysoPAF) Lysolipid 15.01 [2.96, 24.26]
C18:1e LPEe Lysolipid 0.11 [0.07, 0.20]
C20:0 LPC Lysolipid 13.84 [6.64, 19.75]
C20:4 LPA Lysolipid 2.35 [1.68, 2.91]
C20:4 LPC Lysolipid 292.84 [196.19, 367.39]
C20:4 LPS Lysolipid 4.08 [3.60, 4.64]
C20:4e LPSe Lysolipid 0.02 [0.01, 0.05]
C16:0e MAGE Monoacylglycerol 255.78 [206.49, 327.70]
C18:0 MAG Monoacylglycerol 154.63 [72.42, 199.03]
C18:1 MAG Monoacylglycerol 35.7 [21.99, 64.30]
C18:2 MAG Monoacylglycerol 6.14 [1.27, 12.82]
C20:4 MAG Monoacylglycerol 0.47 [0.24, 0.88]
C22:6 MAG Monoacylglycerol 0.05 [0.03, 0.09]
C16:0/C16:0 PI Phospholipid 1.9 [1.03, 3.60]
C16:0/C18:1 PA Phospholipid 11.3 [10.35, 13.37]
C16:0/C18:1 PC Phospholipid 44 132.92 [37 269.07, 52 132.60]
C16:0/C18:1 PI Phospholipid 12.26 [7.23, 20.11]
C16:0/C20:4 PC Phospholipid 28 780.3 [24 703.64, 34 127.57]
C16:0/C20:4 PI Phospholipid 7.28 [4.30, 12.53]
C16:0/C20:4 PS Phospholipid 0.04 [0.02, 0.07]
C16:0e/C18:1 PCe Phospholipid 2154.21 [1889.12, 2520.64]
C16:0e/C18:1 PEe Phospholipid 0.75 [0.30, 1.02]
C16:0e/C18:1 PSe Phospholipid 0.01 [0.01, 0.02]
C16:0e/C20:4 PCe Phospholipid 2833.01 [2487.41, 3331.83]
C16:0p/C20:4 PCp Phospholipid 1441.64 [1198.07, 1707.04]
C18:0/C18:1 alkyl PA Phospholipid 4.04 [3.38, 4.59]
C18:0/C18:1 alkyl PI Phospholipid 0.51 [0.30, 0.88]
C18:0/C18:1 PA Phospholipid 35.8 [32.05, 42.42]
C18:0/C18:1 PC Phospholipid 26 515.68 [22 344.95, 30 784.37]
C18:0/C18:1 PE Phospholipid 0.05 [0.03, 0.09]
C18:0/C18:1 PI Phospholipid 16.47 [9.57, 28.92]
C18:0/C20:4 alkyl PA Phospholipid 0.82 [0.68, 1.05]
(continued)
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profiles. The 92 lipid metabolites assessed had broad ranges of
levels in the women’s plasma. We further examined the rela-
tionship between maternal metabolite counts and offspring
DNA methylation. Out of the lipid metabolites assessed, we
identified significant and predominantly negative associations
among four phospholipids, four lysolipids, and a fatty acid with
newborn methylation. In addition, several of the significant
metabolites were related to multiple CpG sites. For example, the
phospholipids C16:0/C20:4 PS and C18:0/C20:4 alkyl PA were
both associated with 6 CpG sites. These results strengthen the
evidence that maternal metabolites, particularly lysolipids and
phospholipids, are related to reduced offspring DNA methyla-
tion at CpG sites in genes involved in a variety of biological pro-
cesses, including catalytic and binding activities.
The wide range in lipid metabolite levels observed in
CHAMACOS is similar to a study conducted in 40 mother–child
dyads from a clinical birth cohort in Michigan [5]. Marchlewicz
et al. examined acylcarnitine, free fatty acid, and amino acid
Table 2: (continued)
Metabolite Pathway Median IQR
C18:0/C20:4 alkyl PI Phospholipid 0.48 [0.30, 0.89]
C18:0/C20:4 PA Phospholipid 3.23 [2.75, 3.96]
C18:0/C20:4 PC Phospholipid 25 368.63 [22 167.33, 28 643.58]
C18:0/C20:4 PI Phospholipid 36.05 [21.71, 52.25]
C18:0/C20:4 PS Phospholipid 0.61 [0.18, 0.91]
C18:0e/C18:1 PCe Phospholipid 2440.81 [1981.18, 2796.77]
C18:0e/C18:1 PEe Phospholipid 0.7 [0.44, 1.18]
C18:0e/C18:1 PGe Phospholipid 0.45 [0.03, 2.34]
C18:0e/C20:4 PCe Phospholipid 4815.13 [4010.52, 5666.14]
C18:0e/C20:4 PEe Phospholipid 0.09 [0.03, 0.16]
C18:0p/C20:4 PCp Phospholipid 4569.48 [3835.01, 5374.80]
C18:0p/C20:4 PEp Phospholipid 0.1 [0.04, 0.16]
Cardiolipin C18:1/18:1/18:1/18:1 T2 Phospholipid 1.04 [0.80, 1.31]
C16:0 ceramide Sphingolipid 12.11 [9.50, 13.92]
C16:0 SM Sphingolipid 2178.44 [1830.64, 2544.65]
C18:0 ceramide Sphingolipid 1.79 [1.37, 2.36]
C18:0 SM Sphingolipid 1997.51 [1135.78, 2943.23]
C18:0/C16:0 ceramide-1-phosphate Sphingolipid 8.26 [7.32, 10.12]
C18:1 SM Sphingolipid 2325.2 [2009.34, 2810.72]
C18:1/C16:0 ceramide-1-phosphate Sphingolipid 92.51 [78.65, 109.94]
C20:4 SM Sphingolipid 1400.77 [881.66, 1765.40]
Lactosylceramide C18:1/C18:0 Sphingolipid 0.5 [0.28, 0.77]
Sphinganine Sphingolipid 3.64 [1.38, 11.14]
Sphingosine Sphingolipid 36.95 [19.04, 51.62]
C16:0/C16:0/C16:0 TAG Triacylglycerol 1690.96 [958.05, 2779.60]
C16:0/C18:1/C16:0 TAG Triacylglycerol 10 433.19 [7397.58, 13 658.95]
C16:0/C20:4/C16:0 TAG Triacylglycerol 3969.7 [2889.16, 5224.91]
C18:0/C18:0/C18:0 TAG Triacylglycerol 216.26 [121.32, 356.69]
C18:0/C18:1/C18:0 TAG Triacylglycerol 868.13 [430.36, 1782.46]
C18:0/C20:4/C18:0 TAG Triacylglycerol 2.72 [1.61, 9.12]
Figure 3: manhattan plot of CpG sites of CHAMACOS newborns associated with C18:0/C20:4 alkyl PA levels in the blood of their mothers during pregnancy. Red line rep-
resents genome-wide significance threshold of log10(5.00E-08), while the blue line corresponds to the suggestive threshold of log10(1.00E-05)
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metabolite levels of mothers during the first trimester and at
delivery, as well as of their children at birth. They observed
wide distributions of free fatty acid levels similar to
CHAMACOS, with medians ranging from 0.00 to 152.70 nmol/ml
and 0.00 to 247.90 nmol/ml for the maternal first trimester and
delivery metabolites, respectively. In CHAMACOS mothers, me-
dian free fatty acid metabolite counts ranged from 1.12 to
4337.56. Higher levels in the CHAMACOS cohort could be attrib-
uted to differences in study populations; since CHAMACOS par-
ticipants have a high prevalence of obesity and are Mexican-
Table 3: significant results of the relationship between prenatal maternal metabolite levels in plasma and newborn cord blood DNA
methylation
CpG sites Chromosome N b SE FDR P-value Significant exposures Genes Gene location Relation to CpG island
cg02496111 16 81 3.172 0.467 0.012 C16:0/C20:4 PS Island
cg03168497 17 81 2.118 0.330 0.021 C18:1 alkyl LPA MYCBPAP Body Island
cg04108939 1 80 1.169 0.187 0.039 C20:4 LPS BEST4 Body Island
cg06494167 2 80 1.428 0.214 0.018 C18:1 LPI RMND5A TSS1500 Island
cg07370087 1 81 0.469 0.076 0.044 C18:0 FFA
cg08838610 17 81 3.662 0.589 0.040 C16:0/C20:4 PS RPAIN, NUP88 TSS200, 1st exon Island
cg09931872 10 80 2.409 0.365 0.018 C16:0/C20:4 PS WDFY4 50UTR
cg10528455 2 81 0.492 0.076 0.019 C18:0/C20:4 alkyl PA
cg10874881 7 80 2.546 0.346 0.002 C16:0/C20:4 PS POU6F2 Body
cg12106728 12 79 1.014 0.144 0.005 C18:0/C20:4 alkyl PA Island
79 1.667 0.229 0.003 C18:1 LPI
cg14630692 9 81 0.305 0.047 0.019 C16:0 alkyl LPA URM1 Body
cg14897096 11 78 1.911 0.286 0.018 C16:0/C20:4 PS PC 50UTR N_Shelf
cg15710245 11 79 0.731 0.114 0.024 C18:0e/C18:1 PEe BDNF TSS200, TSS1500,
body, 50UTR
Island
cg16597728 20 79 2.063 0.293 0.005 C16:0/C20:4 PS APCDD1L Body S_Shore
cg16787284 2 81 25.723 4.056 0.026 C16:0e/C18:1 PSe SEPT2, HDLBP TSS200, 50UTR Island
81 1.154 0.180 0.021 C18:0e/C18:1 PEe
cg17169243 12 79 0.366 0.057 0.021 C16:0 alkyl LPA CTDSP2,
MIR26A2
Body, TSS1500
79 0.454 0.070 0.019 C18:0/C20:4 alkyl PA
79 0.807 0.105 0.002 C18:1 LPI
cg19220754 5 81 1.843 0.281 0.019 C18:0/C20:4 alkyl PA TNPO1 Body Island
81 2.962 0.456 0.019 C18:1 LPI
cg21883754 19 79 21.976 2.924 0.002 C16:0e/C18:1 PSe TTYH1 TSS200 N_Shore
cg22539279 3 81 23.200 3.607 0.021 C16:0e/C18:1 PSe NEK11, ASTE1 TSS200 Island
cg24175823 10 77 1.024 0.154 0.018 C16:0 alkyl LPA Island
77 1.341 0.180 0.002 C18:0/C20:4 alkyl PA
77 2.039 0.306 0.018 C18:1 LPI
cg27492749 7 76 1.548 0.235 0.019 C18:0/C20:4 alkyl PA SGCE, PEG10 Body, TSS1500 Island
Bolded FDR P-values indicate CpGs that were also significant based on the more conservative Bonferroni correction (uncorrected P-value <1.36  109).
b represents regression coefficients of the relationship between log(1þx) transformed maternal prenatal metabolites and newborn DNA methylation M-values, adjust-
ing for child sex, batch, and white blood cell composition.
Figure 4: diagram of the significant positive (þ) and negative () associations observed between maternal metabolites during pregnancy and newborn DNA methyla-
tion (A) and the biological pathways whereby maternal lipid levels could impact DNA methylation of their children (B)
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American as compared to the population in the Marchlewicz et
al. study, which was mostly Caucasian; and the species of free
fatty acid metabolites assessed in each cohort.
In addition to determining the distributions of lipid metabolites
in maternal plasma, another critical objective of this study was to
assess the relationship between maternal blood lipid levels and
offspring DNA methylation at birth. Using a targeted approach,
previous research in animal models has demonstrated associa-
tions between maternal fatty acid diet and increased DNA methyl-
ation of the fatty acid desaturase 2 (Fads2) gene in the liver of
offspring, which encodes for D6 desaturase, a rate limiting enzyme
in polyunsaturated fatty acid synthesis [16, 17]. A similar study in
humans of the effect of fatty acid supplementation showed no sig-
nificant differences when comparing cord blood promoter methyl-
ation profiles of offspring of pregnant women receiving DHA or
those in the placebo group [20]. In addition, sphingosine-1-phos-
phate, a sphingolipid, has been linked at the cellular level to an-
other epigenetic mechanism, histone acetylation [21].
Only a couple of studies have examined the association be-
tween blood lipid metabolite profiles and DNA methylation in
humans. Petersen et al. [6] assessed concurrent metabolomics
profiles, including lipid metabolites, and DNA methylation lev-
els in 1814 adults in Germany. Using methylation data mea-
sured by the Infinium HumanMethylation 450 BeadChip
platform, as used in this study, and utilizing genome-wide sin-
gle nucleotide polymorphism (SNP) data, they were able to iden-
tify a significant and positive relationship, which also showed a
strong genetic effect, between the phospholipid PC aa C38:4 and
cg11250194. In addition, several CpG site and metabolite associ-
ations were discovered after correcting for genetic effects, in-
cluding a positive relationship between cg17901584 and the
phospholipid PC ae C36:5. We also observed significant associa-
tions with phospholipid metabolite levels in the CHAMACOS co-
hort. Specifically, maternal levels of C16:0/C20:4 PS, C16:0e/
C18:1 PSe, C18:0e/C18:1 PEe, and C18:0/C20:4 alkyl PA were all re-
lated to newborn DNA methylation.
In CHAMACOS, we observed predominantly negative rela-
tionships between maternal second trimester metabolite counts
and newborn DNA methylation. Marchlewicz et al. [5] conducted
a similar study in 40 predominantly white (85%) mothers and
their children from Michigan. They examined whether maternal
metabolomic profiles are associated with cord blood methyla-
tion globally, measured by LINE-1 and LUMA, and at genes rele-
vant for growth, including the imprinted genes H19 and IGF2.
They observed that maternal fatty acids measured during the
first trimester were significantly and positively correlated with
infant methylation at LINE-1, IGF2, ESR1, and PPARa, and nega-
tively correlated with H19 and LUMA. Additional correlations
were found for maternal delivery and cord blood metabolite lev-
els with newborn methylation, with similar directions of associ-
ation. Although we were not able to replicate the results
observed in the Marchelwizc et al. study since they used a candi-
date gene approach, we were also able to observe a significant
relationship between maternal lipid levels and imprinted gene
methylation in newborns. Specifically, the relationship between
cg27492749, a CpG site within another imprinted gene (SGCE),
and the lipid metabolite C18:0/C20:4 alkyl PA. Taken together,
these studies provide preliminary evidence of associations be-
tween maternal metabolomic environments during pregnancy
and DNA methylation status of their offspring.
Several of the genes with significant CpG sites related to ma-
ternal metabolite levels in the CHAMACOS cohort are involved
Table 4: pathway information for genes with CpG sites significantly associated with maternal metabolite levels
Gene Molecular function Biological process Cellular component Protein class Pathway
BDNF Binding; molecular
transducer activity
Biological regulation;
cellular component
organization or bio-
genesis; cellular pro-
cess;
multicellular organis-
mal process; response
to stimulus; signaling
Cell; extracellular
region; membrane;
organelle; synapse
Signaling molecule Huntington disease;
metabotropic glu-
tamate receptor
group II pathway
BEST4 Transporter
CTDSP2 Catalytic activity
NEK11 Cellular process Cell; organelle Transferase
NUP88 Localization Cell; organelle; pro-
tein-containing
complex
Transporter
PC Catalytic activity Metabolic process Cell Ligase Pyruvate
metabolism
RMND5A Catalytic activity Metabolic process Cell; organelle; pro-
tein-containing
complex
SEPT2 Binding; catalytic activity Cellular component or-
ganization or biogen-
esis; cellular process;
localization
Cell; membrane; pro-
tein-containing
complex
Cytoskeletal protein; en-
zyme modulator
Parkinson disease
SGCE Binding Developmental process Calcium-binding protein
TNPO1 Binding; transporter
activity
Localization Cell; membrane;
organelle
Transfer/carrier protein;
transporter
TTYH1 Transporter activity Cell Transporter
APCDD1L, MYCBPAP, POU6F2, URM1, and WDFY4 did not map to any pathway data in PANTHER.
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in biological pathways associated with early life development.
For instance, the BDNF gene encodes for the growth factor, brain-
derived neurotrophic factor, which is important in the develop-
ment of the central and peripheral nervous systems of infants
[22]. Human septins, including the protein encoded by SEPT2, can
assemble into higher-order cytoskeletal structures, such as fila-
ments and bundles, which are necessary to the growing fetus
[23]. In addition, the PC gene encodes for the enzyme pyruvate
carboxylase, which fuels the tricarboxylic acid cycle, the major
pathway that drives the biosynthesis of amino acids [24].
The statistically significant lipids in this study can be linked
with DNA methylation in several ways. First, the process of lipid
degradation releases fatty acids and lysolipids, as well as cho-
line, which is transported to the developing infant. Choline
serves as a major methyl source for DNA methylation and is
also necessary for the synthesis of new biological membranes
for rapidly dividing cells. The observed associations between
DNA methylation and lipid degradation products may be possi-
ble because the metabolic flux is relatively slow or their abun-
dance is low. In contrast, we did not find associations for the
phosphatidylcholine (PC) or triacylglycerol (TG) metabolites,
which serve as major sources of either fatty acids or choline [25,
26]. The metabolic flux through PC and TG metabolism and their
relative abundance is relatively high (Fig. 2), which could ob-
scure the association. Second, fatty acids provide a major en-
ergy source which drives growth in the developing fetus. Third,
ether lipids regulate cell differentiation and cellular signaling
[27]. Ether lipids are an integral component of lipid membranes,
provide enhanced integrity at lipid raft microdomains, and are
important for membrane fusion and trafficking.
A limitation of this study includes the relatively small sam-
ple size, which could limit the power to detect significant differ-
ences based on the large number of tests performed. However,
our study has more power than the most comparable study [5],
which has half the number of mother–child dyads with metabo-
lomic and DNA methylation data. Another limitation is the ab-
sence of data on child metabolomic profiles at birth. However,
given that maternal lipid metabolites can be transferred to the
developing fetus via the placenta and that the prenatal period is
a time of epigenetic remodeling, we feel that exploring the rela-
tionship between maternal metabolite levels during pregnancy,
a sensitive time for epigenetic changes, is more relevant. In
addition, although DNA methylation is the most commonly
studied epigenetic mechanism, maternal lipid metabolites
could also be related to other epigenetic marks in children, in-
cluding histone modifications.
The main strengths of this study include the use of multiple
‘omics’ data from the well-characterized CHAMACOS cohort, in-
cluding the assessment of numerous classes of lipids, which ex-
panded upon the fatty acids that have been previously assessed
in relation to infant methylation data. This allowed for the dis-
covery of novel associations between maternal metabolite lev-
els, including phospholipids and lysolipids, and newborn DNA
methylation, which could have implications on child health.
Previous studies [28, 29] in pregnant women with poor birth out-
comes compared to controls revealed differences in metabolo-
mic profiles of lipid metabolites. In addition, lower levels of
lysophospholipids, phospholipids, and monoacylglycerols dur-
ing early pregnancy have been associated with macrosomia
[30]. Epigenetics could be one mechanism whereby in utero ex-
posure to maternal metabolites could impact health in early
life. Future research should further explore the potential role of
maternal metabolomic profiles on offspring DNA methylation
and its role in child health.
Methods
Study Population
Study participants included women and children from the
CHAMACOS study, a longitudinal birth cohort originally aimed
at examining the relationship of pesticide and environmental
chemical exposure with the health and development of
Mexican-American children from Salinas Valley, CA. A more in
depth discussion of the study population has been character-
ized previously in Eskenazi et al. [19]. From 1999 to 2000, a total
of 601 pregnant women were enrolled, resulting in the delivery
of 527 liveborn singletons. Two pregnancy interviews were con-
ducted at an average of 13.4 and 26.0 weeks gestation, with an
additional visit after delivery. This study includes the 81
mother–child pairs with both metabolomic data from blood col-
lected at the second pregnancy visit and with newborn Illumina
HumanMethylation 450K BeadChip data. The University of
California, Berkeley Committee for Protection of Human
Subjects approved all study protocols and written informed
consent was obtained from the CHAMACOS mothers.
Pregnancy Metabolite Measurements
Biological samples collected from 115 CHAMACOS women
around 26 weeks gestation (mean ¼ 26.4, SD ¼ 3.2) were analysed
to characterize maternal metabolomics profiles during preg-
nancy. Detailed descriptions of the metabolomics analyses in
the CHAMACOS cohort have been previously described in Zhou
et al. [18]. Briefly, blood from the women was analysed in dupli-
cates by selected reaction monitoring (SRM) liquid
chromatography and triple quadrupole mass spectrometry, a
method previously validated by the Nomura research group [31].
SRM was used to identify metabolites, which were measured us-
ing the area under the curve. C12 MAGE, Pentadecanoic acid, and
D3N15 Serine were utilized in the normalization of plasma non-
polar positive, plasma nonpolar negative, and plasma polar
metabolites, respectively. Laboratory and field blanks, as well as
internal standards, were included to ensure quality, and repeat
samples had good reproducibility (coefficients of variation  3–
15%). For this study, we focused on the plasma metabolites in-
volved in lipid pathways since lipids are involved in diverse bio-
logical activities including metabolic and structural functions,
inflammation, signaling, and endocrine regulation [32].
Cord Blood Collection and Processing
At delivery, hospital staff collected cord blood in two types of
vacutainers, one coated in heparin (green top) and the other
without the anticoagulant (red top). Blood clots were aliquoted
from the nonheparinized vacutainers and were stored at 80C
until use in DNA isolation.
DNA Preparation
DNA isolation of anticoagulant-free umbilical cord blood clot
samples was performed using QIAamp DNA Blood Maxi Kits
(Qiagen, Valencia, CA) following the manufacturer’s protocol,
with the exception of small modifications that were previously
described in Holland et al. [33].
450K BeadChip DNAMethylation Analysis
DNA samples of 1 lg were bisulfite converted using Zymo
Bisulfite Conversion Kits (Zymo Research, Irvine, CA), whole
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genome amplified, enzymatically fragmented, purified, and ap-
plied to Illumina Infinium HumanMethylation 450 BeadChips
(Illumina, San Diego, CA) following the manufacturer’s instruc-
tions [34]. Samples were randomized across assay wells, chips,
and plates to prevent batch bias. Robotics handled the 450K
BeadChips, which were analysed using the Illumina Hi-Scan
system. DNA methylation was assessed at 485 512 CpG sites.
Probe signal intensities were extracted by Illumina
GenomeStudio software (version XXV2011.1, Methylation
Module 1.9) methylation module and background subtracted. A
variety of quality assurance and control measures were imple-
mented and have been previously described in Yousefi et al.
[35], such as determination of assay repeatability and batch
effects. The All Sample Mean Normalization algorithm [35], ad-
justed for color channel bias, batch effects and differences in
Infinium chemistry. In addition, Beta Mixture Quantile normali-
zation was used to account for differences between the two
Illumina probes [36]. Samples were retained if 95% of sites
assayed had detection P-values greater than 0.01. Criteria for re-
moval included: (i) sites with annotated probe SNPs (n ¼ 65) and
with common SNPs (minor allele frequency >5%) within 50 bp
of the target identified in the MXL (Mexican ancestry in Los
Angeles, CA) HapMap population (n ¼ 49 748); (ii) sites mapped
to the X (n ¼ 10 708) and Y (n ¼ 95) chromosomes [14]; (iii) cross-
reactive probes identified by Chen et al. [37] (n ¼ 26 950); and (iv)
probes where 95% of samples had detection P-values greater
than 0.01 (n ¼ 460). A total of 398 483 CpG sites remained for
analysis. Methylation beta values across sites were logit trans-
formed to the M-value scale to more accurately adhere to
modeling assumptions [38]. Methylation observations greater or
less than three times the interquartile range for a given CpG site
were removed prior to regression analyses to reduce the influ-
ence of methylation outliers.
Statistical Analysis
To examine the distributions of individual metabolites in ma-
ternal blood during pregnancy, we computed descriptive statis-
tics. We used Student’s t-tests to compare methylation profiles
between CHAMACOS newborns with methylation data that
were included (N ¼ 81) and excluded (N ¼ 288) in the current
analyses, with results indicating no significant differences in
methylation between the two groups. There was no difference
between the subset of the participants included in this study
and the rest of the CHAMACOS cohort.
To determine the relationship between maternal preg-
nancy metabolomics profiles as the exposure and 450K DNA
methylation of their newborn children as the outcome, we fit
limma linear models with empirical Bayes variance shrinkage
[39]. To reduce the influence of metabolite outliers, all 92 ma-
ternal lipid metabolites were log(1þx) transformed. We ad-
justed for sex and batch in each of the models. Since DNA
methylation has been observed to vary by cell type [40], we
also accounted for white blood cell type proportions in statisti-
cal models. To estimate cord blood proportions of seven white
blood cell types, including nucleated red blood cells, we uti-
lized a cord blood reference dataset from Johns Hopkins [41].
We adjusted P-values for multiple hypotheses testing using
the Benjamini–Hochberg FDR threshold for significance of 0.05
[42]. We also identified CpGs that were significant based on
the more conservative Bonferroni correction (uncorrected P-
value <1.36  109 to account for 36 660 436 tests). This analy-
sis was performed using R statistical computing software
(v3.5.1) [43].
Gene Ontology Analysis
We used the online tool PANTHER (protein annotation through
evolutionary relationship) [44] to classify the function and rele-
vant pathways of genes with FDR significant CpG sites related
to lipid metabolites. Briefly, the list of genes was entered into
the ‘Gene List Analysis’ tool in PANTHER and the functional
classification for each gene was generated. Gene ontology re-
lated to molecular function, biological process, cellular compo-
nent, protein class, and pathway was available for most of the
genes identified in the regression results.
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